Nicholas Maestas
Director of Finance/CFO chez TEMPEST THERAPEUTICS, INC.
Fortune : - $ au 31/03/2024
Profil
Nicholas Maestas is currently the Secretary, Vice President-Finance & Strategy at Tempest Therapeutics, Inc. He previously worked as the Senior Director-Corporate Development & Operations at Immune Design Corp.
from 2014 to 2019 and as the Head-Financial Planning & Analysis at Alector, Inc. from 2019 to 2021.
Mr. Maestas completed his undergraduate degree at the University of California, Berkeley and holds an MBA from The Wharton School of the University of Pennsylvania.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 03/01/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Nicholas Maestas
| Sociétés | Poste | Début |
|---|---|---|
| TEMPEST THERAPEUTICS, INC. | Director of Finance/CFO | 12/07/2021 |
Anciens postes connus de Nicholas Maestas
| Sociétés | Poste | Fin |
|---|---|---|
| ALECTOR, INC. | Corporate Officer/Principal | 01/07/2021 |
| IMMUNE DESIGN CORP | Corporate Officer/Principal | 01/07/2019 |
Formation de Nicholas Maestas
| University of California, Berkeley | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| ALECTOR, INC. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Immune Design Corp.
 Immune Design Corp. Pharmaceuticals: MajorHealth Technology Immune Design Corp. is a clinical-stage immunotherapy company focused on cancer with in vivo approaches designed to enable the body's immune system to fight disease. It develops multiple product candidates from its discovery platforms, ZVex and GLAAS. The company was founded by Steven G. Reed and David Baltimore on February 20, 2008 and is headquartered in Kenilworth, NJ. | Health Technology |
| Tempest Therapeutics, Inc. |
